TALPHERA, INC.
Close on Oct 19, 2026
- Market cap
- $81.57M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | – | $-0.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | – | $-0.04 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | $-0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | $1.00K | $-0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | $-0.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $27.00K | $-0.10 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | $-0.07 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | $-0.13 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Mar 23, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Cash operating expenses, or selling, general and administrative, and research and development expenses, excluding stock-based compensationnon-GAAP | 2026 | $17.00M to $18.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Talphera filed with the SEC
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
Executive or director change · Other events · EX-99.1 to Form 8-K
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
Material agreement · Results of operations · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Item 7. Management ’ s Discussion and Analysis of Financial Condition and Results of Operations
Other events · EX-99.1 to Form 8-K
The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
Other events · EX-99.2 to Form 8-K
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA ® to Alora Pharmaceuticals
Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
Material agreement · Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
AcelRx Pharmaceuticals to Acquire Lowell Therapeutics
Results of operations · Other events · EX-99.1 to Form 8-K